DNSP-11

The problem it addresses. GDNF is the most compelling neurotrophic factor in Parkinson's disease biology: it protects and restores dopamine neurons in rodent and primate models more convincingly than anything else. Translating that has failed repeatedly. GDNF is a disulfide-linked dimeric protein that cannot cross the blood-brain barrier, so trials have required convection-enhanced delivery directly into the putamen, and the results have not matched the animal data.

What DNSP-11 is. The GDNF gene produces a pro-protein that is cleaved, and the pro-domain yields peptides of its own. DNSP-11 - dopamine neuron stimulating peptide 11 - is an 11-residue fragment from that pro-domain. The founding paper showed dopamine-neuron stimulating actions in rats [1], and follow-up work characterised dynamic changes in dopamine neuron function in vivo alongside increased ERK1/2 phosphorylation in vitro [2].

Delivery is the point. A peptide of this size can be given intranasally, and a 2015 paper set out the methodology and effects of repeated intranasal delivery in a rat model of Parkinson's disease [3]. If a fragment can do some of what the protein does without neurosurgery, that is a real advance in principle.

The unresolved part. A comparison of three synthetic peptides derived from the pro- and mature GDNF sequence found differing physical and protective properties [4], and the working assumption in this literature is that DNSP-11 does not act through GFRalpha1/RET, GDNF's own receptor system. So the peptide produces GDNF-like effects by an unidentified route. That is interesting rather than reassuring - it means the animal results cannot be predicted from GDNF pharmacology, and off-target effects cannot be reasoned about.

Human evidence. None. No trial, no pharmacokinetics, no case series.

GDNF signals through a complex of GFRalpha1 with the RET receptor tyrosine kinase, driving survival and growth of dopaminergic neurons. DNSP-11 comes from the pro-domain rather than the mature growth factor and does not appear to use that system [4].

What has been observed is functional: increased dopamine neuron activity and dopamine release in vivo, and increased ERK1/2 phosphorylation in cultured cells [1][2]. ERK activation is a common downstream node for growth factor signalling, so this is consistent with a neurotrophic effect without identifying its origin.

Two implications follow. First, because the receptor is unknown, there is no binding assay against which to optimise a dose, and no basis for predicting selectivity. Second, the repeated failure of GDNF in human trials does not directly argue against DNSP-11 - different mechanism, different delivery - but nor can DNSP-11 borrow GDNF's animal credibility, since it is not doing the same thing at the receptor.

A synthetic 11-residue peptide. Routes used in the published work are direct intracerebral administration [1][2] and intranasal delivery [3]. The physical stability of GDNF-derived synthetic peptides has been examined in vitro alongside their protective activity [4]. There is no human formulation.

No human safety data exist, and the animal studies were designed to measure dopaminergic effects rather than toxicity.

The specific unknown worth naming is the unidentified target. A peptide producing neurotrophic effects through an uncharacterised route cannot have its off-target profile predicted, and nothing in the published work addresses what else it might act on in a whole brain over time.

A second consideration applies to the whole class: growth factor signalling promotes cell survival and growth, and sustained neurotrophic stimulation is not an unambiguously benign thing to do. GDNF trials have monitored for this; no equivalent work exists for DNSP-11.

No interaction studies exist. The comparison in the literature is between DNSP-11 and other synthetic peptides from the GDNF pro- and mature sequence, which were examined side by side for physical and protective properties rather than combined [4].